<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7203">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947115</url>
  </required_header>
  <id_info>
    <org_study_id>112772</org_study_id>
    <nct_id>NCT00947115</nct_id>
  </id_info>
  <brief_title>Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects</brief_title>
  <official_title>Follow-up Study to Evaluate the Long-term Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV (580299) Vaccine in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infection with human papillomavirus (HPV) has been clearly established as the necessary
      cause of cervical cancer. This study is designed to evaluate the long-term immunogenicity
      and safety of the GSK Biologicals' 580299 HPV vaccine up to 10 years after administration of
      the first dose of HPV vaccine (Month 0) in primary study NCT 00196937. This protocol posting
      deals with objectives &amp; outcome measures of the extension phase from Year 5 to Year 10. The
      objectives &amp; outcome measures of the primary phase and extension phase up to year 4 are
      presented in a separate protocol posting (NCT 00196937).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were aged 15-55 years at the time of entry into the primary study (NCT00196937). No
      vaccine will be administered in this extension study.

      Results on outcome measures describing analyses on other studies are not reported in this
      record. Please refer to the records mentioned in the respective outcome measure titles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum</measure>
    <time_frame>At Year 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum</measure>
    <time_frame>At Years 8, 9 and 10</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects.</measure>
    <time_frame>At Year 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Seroconverted Subjects.</measure>
    <time_frame>At Years 8, 9 and 10</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Immunoglobulin G (IgG) Antibody Titers in Serum</measure>
    <time_frame>At Year 5, 6 and 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>IgG antibody titers were expressed as GMTs in microgram per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Immunoglobulin G (IgG) Antibody Titers in Serum</measure>
    <time_frame>At Years 8, 9 and 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)</measure>
    <time_frame>At Year 5 and Year 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anti-HPV-16/18 titers in CVS were given as GMTs expressed in ELISA units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)</measure>
    <time_frame>At Years 7, 8, 9, 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS</measure>
    <time_frame>At Year 5 and Year 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Titers were given as GMTs expressed in microgram per milliliter (µg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS</measure>
    <time_frame>At Years 7, 8, 9, 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>From Month 48 in primary study (NCT00196937) up to Month 60 (Year 5)</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>From the Month 60 (Year 5) visit until the Month 72 (Year 6) visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>From Month 72 (Year 6) visit to Month 84 (Year 7) visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>From Month 84 (Year 7) to the Month 96 (Year 8) visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>From Month 96 (Year 8) to the Month 108 (Year 9) visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>From Year 0 up to Year 9</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</measure>
    <time_frame>Until Year 10</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">525</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix 15-25 years group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 26-45 years group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervarix 46-55 years group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood samples will be collected at Years 5, 6, 7, 8, 9 and 10</description>
    <arm_group_label>Cervarix 46-55 years group</arm_group_label>
    <arm_group_label>Cervarix 26-45 years group</arm_group_label>
    <arm_group_label>Cervarix 15-25 years group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cervico-vaginal secretion (CVS) samples</intervention_name>
    <description>CVS will be collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteer for this procedure.</description>
    <arm_group_label>Cervarix 46-55 years group</arm_group_label>
    <arm_group_label>Cervarix 26-45 years group</arm_group_label>
    <arm_group_label>Cervarix 15-25 years group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes that they can and will comply with the
             requirements of the protocol.

          -  A female who enrolled in NCT00332475 and received three doses of GSK 580299 vaccine.

          -  Written informed consent obtained from the subject.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) or planned use
             during the study period.

          -  Chronic administration (defined as more than 14 consecutive days) of
             immunosuppressants or other immune-modifying drugs occurring less than three months
             prior to blood sampling.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding blood sampling.

          -  Administration or planned administration of any HPV vaccine, other than the three
             doses of HPV-16/18 vaccine administered in NCT00332475 study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 10, 2015</lastchanged_date>
  <firstreceived_date>July 16, 2009</firstreceived_date>
  <firstreceived_results_date>February 10, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV vaccine</keyword>
  <keyword>Cervical cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of the 525 enrolled subjects, 1 subject was excluded for not receiving vaccination and the actual starting number was 524. However, not all subjects came to all study visits, hence the actual starting numbers varied depending on the rate of return.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix 15-25 Years Group</title>
          <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="P2">
          <title>Cervarix 26-45 Years Group</title>
          <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="P3">
          <title>Cervarix 46-55 Years Group</title>
          <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Year 5 (Month 60)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 6 (Month 72)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="177"/>
                <participants group_id="P3" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 7 (Month 84)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 8 (Month 96)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="147"/>
                <participants group_id="P3" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Year 9 (Month 108)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="175"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="175"/>
                <participants group_id="P3" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Some subjects who came for the Year 5 timepoint did not return for the Year 6, 7, 8 or 9 timepoints, hence the numbers of subjects starting each year (based on the actual rate of return for visits) do not correspond to the ones of the previous years.</population>
      <group_list>
        <group group_id="B1">
          <title>Cervarix 15-25 Years Group</title>
          <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="B2">
          <title>Cervarix 26-45 Years Group</title>
          <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="B3">
          <title>Cervarix 46-55 Years Group</title>
          <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="159"/>
                <measurement group_id="B2" value="188"/>
                <measurement group_id="B3" value="177"/>
                <measurement group_id="B4" value="524"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for Year 5</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25.7" spread="2.82"/>
                <measurement group_id="B2" value="41.0" spread="6.02"/>
                <measurement group_id="B3" value="54.4" spread="3.15"/>
                <measurement group_id="B4" value="40.9" spread="12.22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for year 6</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26.6" spread="2.85"/>
                <measurement group_id="B2" value="41.8" spread="6.05"/>
                <measurement group_id="B3" value="55.4" spread="3.20"/>
                <measurement group_id="B4" value="41.8" spread="12.28"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for Year 7</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27.5" spread="2.78"/>
                <measurement group_id="B2" value="42.9" spread="5.96"/>
                <measurement group_id="B3" value="56.4" spread="3.23"/>
                <measurement group_id="B4" value="42.6" spread="12.42"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for Year 8</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20.4" spread="2.81"/>
                <measurement group_id="B2" value="35.8" spread="5.88"/>
                <measurement group_id="B3" value="49.6" spread="2.89"/>
                <measurement group_id="B4" value="35.6" spread="12.57"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Data for Year 9</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="29.5" spread="2.8"/>
                <measurement group_id="B2" value="45.0" spread="6.0"/>
                <measurement group_id="B3" value="58.4" spread="3.2"/>
                <measurement group_id="B4" value="44.8" spread="12.32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data for Year 5</description>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="153"/>
                <measurement group_id="B2" value="184"/>
                <measurement group_id="B3" value="170"/>
                <measurement group_id="B4" value="507"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data for Year 6</description>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="147"/>
                <measurement group_id="B2" value="177"/>
                <measurement group_id="B3" value="164"/>
                <measurement group_id="B4" value="488"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data for Year 7</description>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="149"/>
                <measurement group_id="B2" value="165"/>
                <measurement group_id="B3" value="160"/>
                <measurement group_id="B4" value="474"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data for Year 8</description>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="137"/>
                <measurement group_id="B2" value="147"/>
                <measurement group_id="B3" value="146"/>
                <measurement group_id="B4" value="430"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Data for Year 9</description>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="146"/>
                <measurement group_id="B2" value="175"/>
                <measurement group_id="B3" value="162"/>
                <measurement group_id="B4" value="483"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum</title>
        <description>Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>At Year 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity at Years 5, 6 and 7, which included all evaluable subjects that were included in the ATP cohort for immunogenicity of the primary study (NCT00196937) and for whom immunogenicity data at Years 5, 6 and 7 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="146"/>
                  <measurement group_id="O2" value="171"/>
                  <measurement group_id="O3" value="166"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum</title>
            <description>Titers were expressed as Geometric Mean Titer (GMT) in Enzyme-Linked Immunosorbent Assay (ELISA) units per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [Year 5] (N=146; 169; 164)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1473.4" lower_limit="1246.6" upper_limit="1741.5"/>
                  <measurement group_id="O2" value="620.0" lower_limit="512.8" upper_limit="749.6"/>
                  <measurement group_id="O3" value="399.5" lower_limit="330.8" upper_limit="482.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Year 5] (N= 145; 168; 166)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="439.7" lower_limit="370.4" upper_limit="522.1"/>
                  <measurement group_id="O2" value="183.6" lower_limit="155.2" upper_limit="217.1"/>
                  <measurement group_id="O3" value="119.3" lower_limit="98.8" upper_limit="144.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 [Year 6] (N=145; 171; 159)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1358.0" lower_limit="1155.4" upper_limit="1596.0"/>
                  <measurement group_id="O2" value="591.9" lower_limit="497.8" upper_limit="703.9"/>
                  <measurement group_id="O3" value="389.8" lower_limit="320.9" upper_limit="473.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Year 6] (N= 144; 171; 161)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="448.2" lower_limit="378.1" upper_limit="531.2"/>
                  <measurement group_id="O2" value="182.3" lower_limit="153.0" upper_limit="217.3"/>
                  <measurement group_id="O3" value="112.7" lower_limit="92.3" upper_limit="137.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 [Year 7] (N=142; 160; 153)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1011.4" lower_limit="854.1" upper_limit="1197.7"/>
                  <measurement group_id="O2" value="435.1" lower_limit="355.9" upper_limit="532.0"/>
                  <measurement group_id="O3" value="288.5" lower_limit="235.0" upper_limit="354.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Year 7] (N= 141; 159; 155)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="317.0" lower_limit="265.9" upper_limit="377.8"/>
                  <measurement group_id="O2" value="134.5" lower_limit="112.1" upper_limit="161.4"/>
                  <measurement group_id="O3" value="92.6" lower_limit="75.3" upper_limit="114.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Anti-Human Papillomavirus (Anti-HPV) 16/18 Antibody Titers in Serum</title>
        <time_frame>At Years 8, 9 and 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects.</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study.</description>
        <time_frame>At Year 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity at Years 5, 6 and 7, which included all evaluable subjects that were included in the ATP cohort for immunogenicity of the primary study (NCT00196937) and for whom immunogenicity data at Years 5, 6 and 7 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-45 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="146"/>
                  <measurement group_id="O3" value="146"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroconverted Subjects.</title>
            <description>Seroconversion was defined as the appearance of antibodies (i.e. anti-HPV-16 and anti-HPV-18 antibody titers respectively greater than or equal to 8 and 7 EL.U/mL) in the serum of subjects seronegative before vaccination in the primary study.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>anti-HPV-16 [Year 5] (N= 128; 127; 118)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="127"/>
                  <measurement group_id="O3" value="118"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>anti-HPV-18 [Year 5] (N= 134; 144; 146)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                  <measurement group_id="O2" value="144"/>
                  <measurement group_id="O3" value="143"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>anti-HPV-16 [Year 6] (N= 128; 130; 116)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128"/>
                  <measurement group_id="O2" value="130"/>
                  <measurement group_id="O3" value="116"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>anti-HPV-18 [Year 6] (N= 133; 146; 142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="133"/>
                  <measurement group_id="O2" value="146"/>
                  <measurement group_id="O3" value="138"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>anti-HPV-16 [Year 7] (N= 125; 119; 111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="125"/>
                  <measurement group_id="O2" value="119"/>
                  <measurement group_id="O3" value="111"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>anti-HPV-18 [Year 7] (N= 130; 136; 137)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130"/>
                  <measurement group_id="O2" value="135"/>
                  <measurement group_id="O3" value="131"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Seroconverted Subjects.</title>
        <time_frame>At Years 8, 9 and 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Immunoglobulin G (IgG) Antibody Titers in Serum</title>
        <description>IgG antibody titers were expressed as GMTs in microgram per milliliter (µg/mL).</description>
        <time_frame>At Year 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity at Years 5, 6 and 7, which included all evaluable subjects that were included in the ATP cohort for immunogenicity of the primary study (NCT00196937) and for whom immunogenicity data at Years 5, 6 and 7 were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="65"/>
                  <measurement group_id="O3" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Immunoglobulin G (IgG) Antibody Titers in Serum</title>
            <description>IgG antibody titers were expressed as GMTs in microgram per milliliter (µg/mL).</description>
            <units>µg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Total IgG serum antibodies [Year 5] (N=68;65;60)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19481.8" lower_limit="18076.2" upper_limit="20996.8"/>
                  <measurement group_id="O2" value="18388.2" lower_limit="16844.6" upper_limit="20073.3"/>
                  <measurement group_id="O3" value="17657.2" lower_limit="16046.7" upper_limit="19429.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total IgG serum antibodies [Year 6] (N=41;38;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13376.5" lower_limit="12498.7" upper_limit="14315.9"/>
                  <measurement group_id="O2" value="12262.7" lower_limit="11304.8" upper_limit="13301.8"/>
                  <measurement group_id="O3" value="12040.2" lower_limit="10854.4" upper_limit="13355.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total IgG serum antibodies [Year 7] (N=59;63;57)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13957.2" lower_limit="13116.6" upper_limit="14851.7"/>
                  <measurement group_id="O2" value="13179.4" lower_limit="12287.7" upper_limit="14135.7"/>
                  <measurement group_id="O3" value="12992.9" lower_limit="12096.6" upper_limit="13955.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Immunoglobulin G (IgG) Antibody Titers in Serum</title>
        <time_frame>At Years 8, 9 and 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)</title>
        <description>Anti-HPV-16/18 titers in CVS were given as GMTs expressed in ELISA units per milliliter (EL.U/mL).</description>
        <time_frame>At Year 5 and Year 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the subset of subjects from the Total Vaccinated Cohort who volunteered for CVS sample collection at Year 5 and Year 6 and for whom their CVS sample contained less than 200 erythrocytes per microliter.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)</title>
            <description>Anti-HPV-16/18 titers in CVS were given as GMTs expressed in ELISA units per milliliter (EL.U/mL).</description>
            <units>EL.U/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-HPV-16 [Year 5] (N=39;39;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90.2" lower_limit="61.9" upper_limit="131.3"/>
                  <measurement group_id="O2" value="47.2" lower_limit="32.2" upper_limit="69.2"/>
                  <measurement group_id="O3" value="56.8" lower_limit="28.7" upper_limit="112.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Year 5] (N=39;39;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.9" lower_limit="20.9" upper_limit="45.6"/>
                  <measurement group_id="O2" value="24.6" lower_limit="14.8" upper_limit="41.0"/>
                  <measurement group_id="O3" value="33.3" lower_limit="15.8" upper_limit="70.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-16 [Year 6] (N=29;29;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80.3" lower_limit="46.8" upper_limit="137.8"/>
                  <measurement group_id="O2" value="43.8" lower_limit="26.0" upper_limit="73.9"/>
                  <measurement group_id="O3" value="37.1" lower_limit="20.8" upper_limit="66.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-HPV-18 [Year 6] (N=29;29;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22.9" lower_limit="13.8" upper_limit="37.9"/>
                  <measurement group_id="O2" value="19.9" lower_limit="11.4" upper_limit="34.9"/>
                  <measurement group_id="O3" value="19.2" lower_limit="11.7" upper_limit="31.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HPV-16/18 Secretion Antibody Titers in Cervico-vaginal Secretion (CVS)</title>
        <time_frame>At Years 7, 8, 9, 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS</title>
        <description>Titers were given as GMTs expressed in microgram per milliliter (µg/mL).</description>
        <time_frame>At Year 5 and Year 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the subset of subjects from the Total Vaccinated Cohort who volunteered for CVS sample collection at Year 5 and Year 6 and for whom their CVS sample contained less than 200 erythrocytes per microliter.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS</title>
            <description>Titers were given as GMTs expressed in microgram per milliliter (µg/mL).</description>
            <units>µg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>IgG secretion antibodies [Year 5] (N=39;39;28)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="577.8" lower_limit="411.3" upper_limit="811.6"/>
                  <measurement group_id="O2" value="550.5" lower_limit="373.7" upper_limit="811.0"/>
                  <measurement group_id="O3" value="990.6" lower_limit="540.2" upper_limit="1816.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IgG secretion antibodies [Year 6] (N=29;29;26)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="546.5" lower_limit="352.2" upper_limit="848.2"/>
                  <measurement group_id="O2" value="499.8" lower_limit="327.7" upper_limit="762.2"/>
                  <measurement group_id="O3" value="1012.9" lower_limit="696.7" upper_limit="1472.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Immunoglobulin G (IgG) Secretion Antibody Titers in CVS</title>
        <time_frame>At Years 7, 8, 9, 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Immunoglobulin G (IgG) Antibody Titers in Serum</title>
        <description>IgG antibody titers were expressed as GMTs in microgram per milliliter (µg/mL).</description>
        <time_frame>At Year 5, 6 and 7</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort at Years 5, 6 and 7, which included all vaccinated subjects for whom data were available at Year 5, Year 6 and Year 7, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="69"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Immunoglobulin G (IgG) Antibody Titers in Serum</title>
            <description>IgG antibody titers were expressed as GMTs in microgram per milliliter (µg/mL).</description>
            <units>µg/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Total IgG serum antibodies [Year 5] (N=69;68;61)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19453.0" lower_limit="18068.5" upper_limit="20943.6"/>
                  <measurement group_id="O2" value="18092.4" lower_limit="16566.3" upper_limit="19759.1"/>
                  <measurement group_id="O3" value="17885.0" lower_limit="16224.1" upper_limit="19715.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total IgG serum antibodies [Year 6] (N=42;39;33)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13318.5" lower_limit="12458.3" upper_limit="14238.1"/>
                  <measurement group_id="O2" value="12173.1" lower_limit="11231.2" upper_limit="13193.9"/>
                  <measurement group_id="O3" value="12040.2" lower_limit="10854.4" upper_limit="13355.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Total IgG serum antibodies [Year 7] (N=59;66;58)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13957.2" lower_limit="13116.6" upper_limit="14851.7"/>
                  <measurement group_id="O2" value="13059.5" lower_limit="12205.2" upper_limit="13973.6"/>
                  <measurement group_id="O3" value="13052.9" lower_limit="12160.9" upper_limit="14010.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Immunoglobulin G (IgG) Antibody Titers in Serum</title>
        <time_frame>At Years 8, 9 and 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 48 in primary study (NCT00196937) up to Month 60 (Year 5)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort at Year 5, which included all vaccinated subjects (i.e. all subjects who received 3 doses of HPV vaccine in the primary study [NCT00196937]) for whom data were available at Year 5.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="153"/>
                  <measurement group_id="O2" value="184"/>
                  <measurement group_id="O3" value="170"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From the Month 60 (Year 5) visit until the Month 72 (Year 6) visit</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort at Year 6, which included all vaccinated subjects (i.e. all subjects who received 3 doses of HPV vaccine in the primary study [NCT00196937]) for whom data were available at Year 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="147"/>
                  <measurement group_id="O2" value="177"/>
                  <measurement group_id="O3" value="164"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 72 (Year 6) visit to Month 84 (Year 7) visit</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort at Year 7, which included all vaccinated subjects (i.e. all subjects who received 3 doses of HPV vaccine in the primary study [NCT00196937]) for whom data were available at Year 7.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="165"/>
                  <measurement group_id="O3" value="160"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 84 (Year 7) to the Month 96 (Year 8) visit</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort at Year 8, which included all vaccinated subjects (i.e. all subjects who received 3 doses of HPV vaccine in the primary study [NCT00196937]) for whom data were available at Year 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="137"/>
                  <measurement group_id="O2" value="147"/>
                  <measurement group_id="O3" value="146"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Month 96 (Year 8) to the Month 108 (Year 9) visit</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was based on the Total Vaccinated cohort at Year 9, which included all vaccinated subjects (i.e. all subjects who received 3 doses of HPV vaccine in the primary study [NCT00196937]) for whom data were available at Year 9.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="146"/>
                  <measurement group_id="O2" value="175"/>
                  <measurement group_id="O3" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From Year 0 up to Year 9</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated cohort that included all vaccinated subjects (i.e. all subjects who received 3 doses of HPV vaccine in the primary study [NCT00196937]) for whom data were available throughout the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix 15-25 Years Group</title>
            <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O2">
            <title>Cervarix 26-45 Years Group</title>
            <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
          <group group_id="O3">
            <title>Cervarix 46-55 Years Group</title>
            <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="159"/>
                  <measurement group_id="O2" value="188"/>
                  <measurement group_id="O3" value="177"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Fatal or Vaccine-related Serious Adverse Events (SAEs) (Including SAEs Related to Study Procedures and GlaxoSmithKline Biologicals' Concomitant Medication).</title>
        <time_frame>Until Year 10</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>01/2016</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: throughout the entire study from Day 0 up to the Year 9 visit.</time_frame>
      <desc>For this long-term follow-up study only Vaccine-related SAEs (Including SAEs Related to Study Procedures and GSK Biologicals' Concomitant Medication) were assessed. Other (non-serious) Adverse Events and solicited symptoms were not collected/assessed. The assessment was based on the Total vaccinated cohort of the primary study (NCT00196937).</desc>
      <group_list>
        <group group_id="E1">
          <title>Cervarix 15-25 Years Group</title>
          <description>Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="E2">
          <title>Cervarix 26-45 Years Group</title>
          <description>Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
        <group group_id="E3">
          <title>Cervarix 46-55 Years Group</title>
          <description>Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study (NCT00196937)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <description>This symptom was assessed by the study investigator to be related to study vaccination for the subject from the Cervarix 26-45 years group in whom it was reported.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="221"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
